-
Validation 2.0: How the Market Has Changed After the Exit of Global Suppliers
Read more: Validation 2.0: How the Market Has Changed After the Exit of Global SuppliersInspections of pharmaceutical companies for compliance with GMP/GAMP 5 requirements are becoming more complex and frequent. According to open data, in 2024 alone, 401 GMP inspections of drug manufacturers were conducted in Russia—twice as many as ever before. At the same time, Russian pharmaceutical manufacturers have lost access to global service providers and are now…
-
Hedge Funds Seek Insights into Pharma
Read more: Hedge Funds Seek Insights into PharmaThe sharp rises and falls in pharmaceutical company stocks are prompting major hedge funds to hire doctors, scientists, and analysts to gain expert assessments of market prospects, Reuters reports, citing its sources. The year 2024 was marked by significant stock price fluctuations in pharma companies, driven by financial performance announcements and updates on various stages…
-
Medicines to Be Exempt from “Visas”
Read more: Medicines to Be Exempt from “Visas”EAEU Countries Will Be Able to Recognize Drugs Registered by Other Member States Authorized agencies of the Eurasian Economic Union (EAEU) member states will have the ability to independently register medicines already introduced to the market in other member states, without the participation of manufacturers. This initiative, prepared by the Board of the Eurasian Economic…
-
Mishustin: 90% of Essential Medicines Should Be Produced in Russia
Read more: Mishustin: 90% of Essential Medicines Should Be Produced in RussiaAccording to the Prime Minister, this goal will be pursued as part of the national project “New Health Preservation Technologies.” The share of domestically produced medicines from the list of essential and vital drugs (EVDL) in Russia should increase to 90% by 2030, Russian Prime Minister Mikhail Mishustin announced. He noted that this effort will…
-
Around 70% of Pharmaceutical Substances in Russia Are Imported
Read more: Around 70% of Pharmaceutical Substances in Russia Are ImportedImported active pharmaceutical substances (APIs) account for approximately 70-75% of the Russian market, according to Razia Solodova, head of the analytical center of the FBU “State Institute for Drugs and Good Practices” of the Russian Ministry of Industry and Trade. She presented these findings at the 26th International Exhibition of Equipment, Raw Materials, and Technologies…
-
Russian Ministry of Health Proposes Updates to Drug Sampling Rules for State Control
Read more: Russian Ministry of Health Proposes Updates to Drug Sampling Rules for State ControlThe Russian Ministry of Health has proposed amendments to Decree No. 1049, dated June 29, 2021, which regulates state oversight in the circulation of pharmaceuticals. Public discussion of the proposal will continue until the end of November 2024. The draft document outlines detailed mechanisms for selecting organizations to conduct control measures for assessing drug quality.…
-
Russian Ministry of Health: 480 Drugs Registered Since the Beginning of the Year
Read more: Russian Ministry of Health: 480 Drugs Registered Since the Beginning of the YearAccording to Russian Minister of Health Mikhail Murashko, approximately 480 drugs have been registered in the country since the start of 2024, with over 70% produced by domestic manufacturers. During the same period, Roszdravnadzor issued 1,800 registration certificates for medical devices, half of which are also of Russian origin. Murashko shared this information in his…
-
“R-Pharm” Receives Approval for Clinical Trials of Drugs for Hepatitis C and Breast Cancer
Read more: “R-Pharm” Receives Approval for Clinical Trials of Drugs for Hepatitis C and Breast CancerThe Russian Ministry of Health has granted “R-Pharm” permission to conduct clinical trials (CT) for generics of two drugs: the oncology drug Zenlistik (abemaciclib) from Eli Lilly and the hepatitis C treatment Mavyret (glecaprevir/pibrentasvir) from AbbVie. Both medications are protected by Eurasian patents in Russia until 2034 and 2033, respectively. The trials will take place…
-
The Lancet: Antibiotic Resistance Deaths to Surge by 2050
Read more: The Lancet: Antibiotic Resistance Deaths to Surge by 2050According to a study published in The Lancet, by 2050, bacteria resistant to existing antibiotics could cause over 39 million deaths and indirectly contribute to an additional 169 million deaths. The forecast predicts that without effective measures to combat this issue, annual mortality directly caused by antimicrobial resistance (AMR) could reach 1.91 million people, with…
-
Ministry of Finance: The “Second Extra” Mechanism Will Be Extended to Vital and Essential Medicines and Strategically Significant Medicines
Read more: Ministry of Finance: The “Second Extra” Mechanism Will Be Extended to Vital and Essential Medicines and Strategically Significant MedicinesThe Ministry of Finance of Russia has revised a draft decree that establishes the procedure for providing advantages to Russian pharmaceutical manufacturers over foreign ones in state procurement. According to the new document, updated procurement rules for medicines from the list of vital and essential medicines (VEM) and strategically significant medicines (SSM) will take effect…